Register Today! Webinar Opportunity: The Future of Injectable PrEP
Posted January 24, 2025
Overview:
Injectable PrEP formulations are a promising intervention for increasing PrEP effectiveness and reducing disparities in HIV transmission, particularly among communities of color, youth, cis-women, transgender, and gender-diverse communities. In this webinar, Dr. Al Liu will provide updates on the latest clinical data for lenacapavir injectable PrEP medication and, along with Whitman-Walker Health colleagues, discuss overcoming barriers to implementation for clinicians, health departments, and CBOs.
Learning Objectives:
- Discuss recent clinical data demonstrating superiority of the injectable HIV prevention medication lenacapavir to oral medications.
- List two ways that injectable PrEP formulations can contribute to combating disparities in HIV prevention.
- Describe three individual and organizational barriers to dissemination of injectable PrEP and how they may be addressed.
About the speaker:
Dr. Albert Liu, MD, MPH is the Clinical Research Director of Bridge HIV within the San Francisco Department of Public Health and a Clinical Professor of Medicine at the University of California, San Francisco. As a leader in HIV prevention research, he conducts clinical trials of novel PrEP agents and evaluates implementation strategies to support the equitable scale-up of PrEP in real-world settings. He also serves as co-chair of the PrEP Committee of the San Francisco Getting to Zero Consortiums and is an attending physician at San Francisco General Hospital.
For questions, please email get.SFcba@sfdph.org
